Skip to main content
Premium Trial:

Request an Annual Quote

MassArray and Related Sales Push Sequenom's Q1 Revenues up 43 Percent

NEW YORK (GenomeWeb News) - Sequenom yesterday said first-quarter revenue surged 43 percent as R&D spending increased 17 percent and net loss was stable. 
Total receipts for the three months ended March 31, 2007, rose to $9.9 million from $6.9 million year over year.
The company said the jump in revenues was driven mainly by sales of MassArray instruments and related products, and by growth in its contract research services group.
Sequenom said sales of consumables rose 47 percent to $4.2 million from $2.9 million, and other product-related sales increased 33 percent, contributing $4.9 million to first-quarter revenue.
R&D spending increased to $2.9 million from $2.5 million year over year.
The company said its net loss was flat at $3.7 million.
Sequenom CEO Harry Stylii said the company plans to use nearly $18.4 million the company netted in a stock placement in April to introduce new products and product enhancements to the company's MassArray line, and to introduce a prenatal test for Rhesus D incompatibility in the second quarter.
Sequenom said it expects full-year 2007 revenues of $37 million to $39 million with a loss between $23 million and $25 million.
Sequenom said it had $21.8 million in cash, cash equivalents, and short-term investments as of March 31, 2007.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.